| Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities Z Cheng, A Al Zaki, JZ Hui, VR Muzykantov, A Tsourkas Science 338 (6109), 903-910, 2012 | 1452 | 2012 |
| Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers S Muro, C Garnacho, JA Champion, J Leferovich, C Gajewski, ... Molecular therapy 16 (8), 1450-1458, 2008 | 673 | 2008 |
| Targeting vascular (endothelial) dysfunction A Daiber, S Steven, A Weber, VV Shuvaev, VR Muzykantov, I Laher, H Li, ... British journal of pharmacology 174 (12), 1591-1619, 2017 | 589 | 2017 |
| Drug delivery by red blood cells: vascular carriers designed by mother nature VR Muzykantov Expert opinion on drug delivery 7 (4), 403-427, 2010 | 490 | 2010 |
| Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems CH Villa, AC Anselmo, S Mitragotri, V Muzykantov Advanced drug delivery reviews 106, 88-103, 2016 | 390 | 2016 |
| Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells AC Anselmo, V Gupta, BJ Zern, D Pan, M Zakrewsky, V Muzykantov, ... ACS nano 7 (12), 11129-11137, 2013 | 381 | 2013 |
| A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1 S Muro, R Wiewrodt, A Thomas, L Koniaris, SM Albelda, VR Muzykantov, ... Journal of cell science 116 (8), 1599-1609, 2003 | 381 | 2003 |
| European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS) J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ... Redox biology 13, 94-162, 2017 | 341 | 2017 |
| Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude JS Brenner, DC Pan, JW Myerson, OA Marcos-Contreras, CH Villa, ... Nature communications 9 (1), 2684, 2018 | 339 | 2018 |
| Endothelial NADPH Oxidase as the Source of Oxidants in Lungs Exposed to Ischemia or High K+ AB Al-Mehdi, G Zhao, C Dodia, K Tozawa, K Costa, V Muzykantov, ... Circulation research 83 (7), 730-737, 1998 | 333 | 1998 |
| The shape of things to come: importance of design in nanotechnology for drug delivery Y Liu, J Tan, A Thomas, D Ou-Yang, VR Muzykantov Therapeutic delivery 3 (2), 181-194, 2012 | 307 | 2012 |
| Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species C Vadseth, JM Souza, L Thomson, A Seagraves, C Nagaswami, ... Journal of Biological Chemistry 279 (10), 8820-8826, 2004 | 289 | 2004 |
| 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage Y Manevich, T Sweitzer, JH Pak, SI Feinstein, V Muzykantov, AB Fisher Proceedings of the National Academy of Sciences 99 (18), 11599-11604, 2002 | 271 | 2002 |
| Advanced drug delivery systems that target the vascular endothelium BS Ding, T Dziubla, VV Shuvaev, S Muro, VR Muzykantov Molecular interventions 6 (2), 98, 2006 | 259 | 2006 |
| Targeting of superoxide dismutase and catalase to vascular endothelium VR Muzykantov Journal of Controlled Release 71 (1), 1-21, 2001 | 258 | 2001 |
| Polymeric carriers: role of geometry in drug delivery EA Simone, TD Dziubla, VR Muzykantov Expert opinion on drug delivery 5 (12), 1283-1300, 2008 | 250 | 2008 |
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes JC Murciano, S Medinilla, D Eslin, E Atochina, DB Cines, VR Muzykantov Nature biotechnology 21 (8), 891-896, 2003 | 246 | 2003 |
| Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics BV Shekhonin, SP Domogatsky, VR Muzykantov, GL Idelson, ... Collagen and related research 5 (4), 355-368, 1985 | 239 | 1985 |
| Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1 S Muro, T Dziubla, W Qiu, J Leferovich, X Cui, E Berk, VR Muzykantov The Journal of pharmacology and experimental therapeutics 317 (3), 1161-1169, 2006 | 234 | 2006 |
| Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm M Howard, BJ Zern, AC Anselmo, VV Shuvaev, S Mitragotri, ... ACS nano 8 (5), 4100-4132, 2014 | 207 | 2014 |
Silvia MuroAssociate Professor, University of Maryland College ParkBestätigte E-Mail-Adresse bei umd.edu
